[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626758":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":20,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Orna Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Ascending Dose","EXPERIMENTAL","Ascending single dose of ORN252 on a specified day",[13],"Biological: ORN252",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","ORN252","ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Orna Clinical Trials","CONTACT","877-728-6762","ClinicalTrials@ornatx.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Nucleus Network","RECRUITING","Herston","Queensland","4006","Australia",{"type":36,"coordinates":37},"Point",[38,39],153.01852,-27.44453,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Principal Investigator","+61 (07) 3707 2720","brisbane@nucleusnetwork.com",{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100626758",false,"NCT07439796","A Study of ORN252 in Healthy Participants","A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORN252 in Healthy Participants","Inclusion Criteria:\n\n* Male and female participants who are healthy as determined by the Investigator based on review of medical history, physical examination, and laboratory tests\n* Participant is willing and able to comply with study visits and other protocol requirements\n* Other protocol specific inclusion criteria may apply\n\nExclusion Criteria:\n\n* Clinically significant history or presence of organ dysfunction\n* Use of any investigational product within 3 months, or 5 half-lives, whichever longer\n* Other protocol specific exclusion criteria may apply",true,"ALL","18 Years","55 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.",[66],"Healthy Volunteers - Male and Female","2026-04-13",{"date":69,"type":70},"2026-04-16","ACTUAL",{"date":72,"type":70},"2026-03-16",{"date":74,"type":60},"2027-03",{"name":5,"class":6},1]